Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 9/20 | 0.38 |
| ▸ | F13A1 | P00488 | 2/20 | 0.38 |
| ▸ | TGM1 | P22735 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | TGM6 | O95932 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035054 | 1.00 | PRCP (0.51) | PRCPMDM2TLR2TLR1KMT2A | |
| SCHEMBL29696622 | 0.88 | PRCP (0.49) | PRCPMDM2TLR2TLR1KMT2A | |
| SCHEMBL13034905 | 0.82 | ACE (0.49) | KMT2AITGB3ITGA2B | |
| SCHEMBL29696666 | 0.81 | PRCP (0.43) | PRCPMDM2TLR2TLR1KMT2A | |
| SCHEMBL13035062 | 0.80 | ACE (0.44) | PRCP | |
| SCHEMBL30640764 | 0.79 | PRCP (0.51) | PRCPMDM2TLR2TLR1KMT2A | |
| SCHEMBL29696668 | 0.79 | PRCP (0.51) | PRCPMDM2TLR2TLR1KMT2A | |
| SCHEMBL15960070 | 0.79 | PRCP (0.51) | PRCPMDM2TLR2TLR1KMT2A | |
| SCHEMBL21838230 | 0.79 | PRCP (0.49) | PRCPMDM4TP53 | |
| SCHEMBL21838231 | 0.79 | PRCP (0.49) | PRCPMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759295-B2 | Peptide-peptidase inhibitor conjugates and methods of using same | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | DNPEP, PEPD, VIP | PRCP 23/4885MDM2 3204/4885TLR2 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.